Validation pour Ingenuity307

vers la météo de la validation par utilisateur

Ingenuity307

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 56 - PMID ?

In SP glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of SP NODE mRNA that is increased by agonist monoclonal anti SP NODE protein antibody .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 1

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 2

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     |                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 3

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 4

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 5

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 6

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     |                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 7

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 8

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 9

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 10

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 11

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 12

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     +----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 13

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 14

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +--------------SUBJ:V-N-------------+     +------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 15

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 16

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 17

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 18

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 19

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 20

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     +----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 21

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 22

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +--------------SUBJ:V-N-------------+     +------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 23

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 24

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 25

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 26

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     |                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 27

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 28

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 29

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 30

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     |                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 31

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +----------------------OBJ:V-N----------------------+              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +--------OBJ:V-N--------+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              +COMP:V-N(by+         +MOD_ATT+SUBJ:+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,agonist)
OBJ:V-N (increase,protein)
MOD_ATT:N-ADJ (anti,monoclonal)
OBJ:V-N (__SP__,agonist)
SUBJ:V-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 32

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 33

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 34

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 35

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 36

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     +----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 37

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 38

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +--------------SUBJ:V-N-------------+     +------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 39

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 40

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 41

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 42

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+SUBJ:V-N+     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 43

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 44

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+                                                                  
                         |                                                            +--------------SUBJ:V-N-------------+     +----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 45

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              +---------COMP:V-N(by)--------+                     |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           +---MOD_ATT:N-N---+     +-MOD_ATT:N-ADJ-+              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         +MOD_ATT+     |       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,anti)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (anti,agonist)
MOD_ATT:N-ADJ (anti,monoclonal)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 46

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+                                                                  
                         |                                                            +-----------------SUBJ:V-N----------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +--------------SUBJ:V-N-------------+     +------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+        |     |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+        |     |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+        |     |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |        |     |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 47

                         +---------------------------------------------COMP:V-N(In)---------------------------------------------+----------------------OBJ:V-N----------------------+              
                         |                                                            +-----------------SUBJ:V-N----------------+------------COMP:V-N(by)-----------+               |              
       +--MOD_ATT:N-ADJ--+                                                            +-------COMP:N-N(of)-------+              |           +------MOD_ATT:N-N------+               |              
       |      +MOD_ATT:N-+-------APPOS------+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ+              |           |         +MOD_ATT:N-ADJ+               |              
       |      |     +MOD_+         +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_AT+              |           |         |       +MOD_A+       +MOD_ATT+              
       |      |     |    |         |        |              |      |        |          |           |       |      |              |           |         |       |     |       |       |              
 In __SP__ glioma cell lines , Sb202190 decreases ( in a dose dependent manner ) expression of __SP__ __NODE__ mRNA that is increased by agonist monoclonal anti __SP__ __NODE__ protein antibody .
MOD_ATT:N-ADJ (line,__SP__)
MOD_ATT:N-N (line,glioma)
MOD_ATT:N-N (line,cell)
APPOS (line,decrease)
MOD_ATT:N-N (decrease,Sb202190)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,line)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,__SP__)
OBJ:V-N (increase,protein)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-ADJ (__SP__,monoclonal)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-ADJ (protein,__NODE__)